ABP

Abpro Holdings, Inc Common Stock
ABP
Market cap $13.1M

0.2150 USD

-0.0163

7.05%

At close Jun 13, 4:00 PM EDT

After hours

0.2065

-0.0085

3.95%

1 day

-7.05%

5 days

2.23%

1 month

4.88%

3 months

-54.29%

6 months

-85.95%

Year to date

-86.31%

1 year

-98.07%

5 years

-97.83%

10 years

-97.83%

About: Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.

Employees: 6

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 13 [Q4 2024] → 13 (+0) [Q1 2025]

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.03% less ownership

Funds ownership: 3.06% [Q4 2024] → 3.03% (-0.03%) [Q1 2025]

69% less capital invested

Capital invested by funds: $1.99M [Q4 2024] → $616K (-$1.38M) [Q1 2025]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ABP.

See Analyst Rankings

Financial journalist opinion

Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager

Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profile Abpro and Celltrion have a strategic partnership for worldwide development and commercialization of ABP-102/CT-P72 HER2-positive cancers represent up to 30 percent of all cases of breast, gastric, pancreatic, colorectal and other forms of cancer WOBURN, Mass., April 27, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, and Celltrion, a leading biopharmaceutical company, today unveiled preclinical data for ABP-102/CT-P72 in an oral presentation at the American Association for Cancer Research® (AACR) Annual Meeting 2025, in the New Drugs on the Horizon session.

Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager

Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025

WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, today announced an oral presentation of preclinical data for ABP-102/CT-P72 at the American Association for Cancer ResearchⓇ Annual Meeting 2025 (“AACR 2025”) in the New Drugs on the Horizon session.

Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025

Abpro Statement on the Departure of Former CEO Ian Chan

WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases announced today the departure of Chief Executive Officer Ian Chan.

Abpro Statement on the Departure of Former CEO Ian Chan

Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing

WOBURN, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) (“Abpro”), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies, celebrated the closing of its business combination with Atlantic Coastal Acquisition Corp II (“ACAB”), a special purpose acquisition company, with a Nasdaq bell ringing ceremony. Abpro also celebrated the consummation of a PIPE offering raising $7 million in gross proceeds and a $2.76 million convertible note financing with YA II PN, LTD (“Yorkville”) to cover expenses in connection with the closing of the business combination.

Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing

See News Rankings

Charts implemented using Lightweight Charts™